Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Light Sciences LLC
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00028405CT.gov Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lip And Oral Cavity Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Talaporfin (this asset) | Light Sciences LLC | P1 | CC · 47 |
| Nivolumab | National Cancer Institute (NCI) | P2 | B |
| Cis-Diamminedichloroplatinum Ii | Loren Mell, MD | P2 | B |
| Pembrolizumab | Loren Mell, MD | P2 | CCC |
| Fludeoxyglucose | Sanjiv Sam Gambhir | P1/2 | CCC |
| Anti-Her2 Antibody-Drug Conjugate A166 | Klus Pharma Inc. | P1/2 | CCC |
| (18F)FPPRGD2 | Sanjiv Sam Gambhir | P1/2 | CCC |
| Mogamulizumab | Osaka University | P1 | CC |
| Brodalumab | Brian Henick, MD | P1 | CC |
+13 more in the Lip And Oral Cavity Carcinoma cohort
Other indications for Talaporfin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Liver And Intrahepatic Bile Duct Neoplasm | — | P3 | BB · 68 |
| Hepatocellular Carcinoma | — | P3 | BB · 64 |
| Colorectal Neoplasm | — | P3 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Talaporfin in Lip And Oral Cavity Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/talaporfin-lip-and-oral-cavity-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →